TScan Therapeutics, Inc. (TCRX) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by TScan Therapeutics, Inc. on November 21, 2024, covering events occurring on November 15, 2024, and November 20, 2024. The Company is an emerging growth company incorporated in Delaware with principal executive offices in Waltham, Massachusetts.
Key Financial Metrics and Transaction Details
The filing reports a specific capital transaction rather than periodic financial performance metrics such as revenue or operating cash flow.
- Transaction Type: Conversion of debt to equity under Item 3.02 (Unregistered Sales of Equity Securities).
- Loan Principal Converted: $15 million.
- Conversion Price: $4.785 per share.
- Shares Issued: 3,134,796 shares of voting common stock.
- Issuance Date: November 20, 2024.
- Legal Basis: Issued in reliance on the registration exemption provided by Section 3(a)(9) of the Securities Act of 1933.
Material Changes and Background
The conversion relates to a Loan and Security Agreement originally dated September 9, 2022, with K2 Health Ventures LLC as administrative agent. The initial agreement provided a $30 million convertible term loan. This filing documents the lender's election to convert a portion of that principal into equity, reducing the Company's outstanding debt obligation by $15 million while increasing the share count.
Guidance, Outlook, and Risks
The filing does not contain forward-looking guidance, management commentary on future operations, or specific risk factors beyond the standard disclosure of the unregistered sale of securities. The transaction was executed in accordance with the existing Loan Agreement terms.
Key Facts for Investor Verification
- Verify the total remaining principal balance of the $30 million loan facility following the $15 million conversion.
- Confirm the dilution impact of the 3,134,796 newly issued shares on existing shareholders.
- Review the full terms of the Loan Agreement to understand remaining conversion options or repayment schedules.
- Check subsequent filings for any additional conversions or changes to the Company's capital structure.